Retatrutide: The Triple Agonist and Where It Stands

Retatrutide is an investigational triple agonist that acts on the GLP-1, GIP and glucagon receptors at once. In its phase 2 trial it produced 24.2% mean weight loss at 48 weeks — a higher figure than any approved drug has reported — and it is now in a phase 3 programme of fourteen trials. It is not approved anywhere. Anything sold under the name today is an unapproved research chemical rather than a medicine, and the difference matters more here than with almost any other molecule.

Where retatrutide actually stands

Study counts and phases were read from ClinicalTrials.gov on 12 August 2026. Where retatrutide sits against every other molecule in development is in the GLP-1 pipeline tracker.

What a triple agonist actually does

The drugs already on the market work on one or two receptors. Semaglutide activates GLP-1. Tirzepatide activates GLP-1 and GIP, and produced more weight loss than semaglutide in the only head-to-head trial of the two. Retatrutide adds a third target: glucagon.

Glucagon is the counter-intuitive one. In isolation it raises blood sugar, which is the opposite of what a diabetes drug is supposed to do. But it also increases energy expenditure and promotes the breakdown of stored fat, and when it is paired with two incretin receptors that lower blood glucose, the glucose-raising effect is offset while the metabolic effect is kept.

That is the theory. What the phase 2 data suggests is that it works: the weight loss curve at 48 weeks was still descending rather than flattening, which is not what the approved drugs do at the same point.

The three receptors are not doing the same job in triplicate. Each contributes something different, and the combination is the argument for the molecule:

• GLP-1 reduces appetite and slows gastric emptying. This is the appetite arm, and it is what semaglutide does alone.
• GIP is the second incretin. Adding it to GLP-1 produced more weight loss than GLP-1 alone in the tirzepatide programme, though exactly why remains debated — and MariTide, another molecule in development, blocks GIP rather than activating it and also produces weight loss, which is a genuine unresolved puzzle in this field.
• Glucagon is the addition that makes retatrutide a triple. It raises energy expenditure and mobilises stored fat — it acts on the output side of the equation where the other two act on intake.

That last point is the interesting one. Appetite suppression alone runs into a limit: eat less for long enough and the body lowers what it spends. A glucagon arm is an attempt to push on both sides at once rather than only on how much goes in. Whether it delivers that in a large population over years, and at what cost in heart rate and other effects, is what fourteen phase 3 trials exist to find out.

The mechanism of the dual agonist it builds on is covered in how tirzepatide works.

The phase 2 results in full

The trial that made retatrutide famous was published in the New England Journal of Medicine in August 2023: 338 adults with obesity, or overweight plus a weight-related condition, randomised to one of six retatrutide regimens or placebo for 48 weeks.

The responder figures are more striking than the means. At 48 weeks:

Every participant on 8 mg and 12 mg lost at least 5% of their body weight. Not most — all of them. And 83% of the 12 mg group lost at least 15%, against 2% on placebo.

Two cautions that belong next to those numbers. This was 338 people, which is a phase 2 trial: small, and the kind of result that regresses when the population grows. And it ran 48 weeks against the 72 weeks used by the approved drugs' trials, so comparing 24.2% to figures measured at 72 weeks is not comparing like with like.

The first phase 3 results have now been published

In June 2026 the Lancet published TRANSCEND-T2D-1, the first phase 3 retatrutide trial to report: 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone, randomised to 4, 9 or 12 mg weekly or placebo for 40 weeks.

Two things about that table are worth pausing on. It is a diabetes population, where every drug in this class loses less weight than it does in people without diabetes — and 15.3% at 40 weeks still exceeds what tirzepatide and semaglutide achieve in the same population over longer periods. And it is 40 weeks rather than 72, so the curve had not finished.

Tolerability held up at scale. Gastrointestinal events were the most frequent and generally mild to moderate, subsiding over time, and 2 to 5% of retatrutide patients discontinued for adverse events against 0% on placebo — lower than Foundayo's 8% or Zepbound's roughly 10% in their own trials. No severe hypoglycaemia was reported. Two deaths occurred, both in the 4 mg group, and both were judged unrelated to the study drug.

How it compares — and why the honest answer is "wait"

Every comparison you will read between retatrutide and an approved drug is cross-trial: different participants, different durations, different years. Set out plainly:

Retatrutide is top of that table on a trial one seventh the size of the one below it. Treat the ordering as a hypothesis, not a result.

The unusual thing is that the real answer is already being generated. Two of the phase 3 trials are direct head-to-heads:

• Against semaglutide — NCT06260722, 1,250 adults with type 2 diabetes, enrolled and running.
• Against tirzepatide — NCT06662383, 800 adults with obesity, enrolled and running.

Neither has reported. When they do, the cross-trial guesswork stops, exactly as SURMOUNT-5 ended the argument between tirzepatide and semaglutide. Until then, anyone presenting "retatrutide vs Zepbound" as settled is presenting an estimate. The comparison that is settled, between the two approved molecules, is in the best GLP-1 for weight loss.

The phase 3 programme is not just about weight

Fourteen phase 3 trials are registered, and the largest of them is not an obesity study.

A 10,000-patient cardiovascular outcomes trial is the kind of study a manufacturer runs when it intends the drug to be prescribed for decades, not marketed for a season. The spread into osteoarthritis, back pain, sleep apnoea and liver disease follows the pattern semaglutide and tirzepatide established: the weight loss opens the door, and the indications that pay for the drug long-term are the conditions weight drives.

Side effects, as far as anyone knows

The phase 2 report describes the common adverse events as gastrointestinal, dose-related, and mostly mild to moderate — the same profile as the rest of the class. One practical finding: they were partially mitigated by a lower starting dose, 2 mg rather than 4 mg, which is why the phase 3 programme escalates more gently than phase 2 did.

The trial also recorded dose-dependent increases in heart rate, peaking at 24 weeks. That is worth stating plainly because it does not appear in most coverage, and because heart rate is exactly what a 10,000-patient cardiovascular outcomes trial is powered to settle.

One further signal is being discussed in the literature rather than in the trial report: a possible association with urinary tract infections, examined in a 2026 commentary in the European Journal of Internal Medicine that asks whether the timing of the cases explains them. It is a question under investigation, not an established adverse effect, and it is included here because a page that only reports the reassuring findings is not a reference.

What nobody has is a safety profile at scale over years. 338 people for 48 weeks tells you what is common; it cannot tell you what is rare. For the approved molecules those numbers exist, and the tirzepatide picture is in tirzepatide side effects.

Can you get it?

Not by prescription. Retatrutide is not approved by the FDA, the EMA or any other regulator, so no pharmacy can dispense it for use.

One narrow route opened in 2026: the BMJ reported in August that a compassionate use programme had been made available in the United States. Compassionate use, also called expanded access, is a supervised pathway for individual patients with serious conditions and no remaining options, arranged between a physician, the manufacturer and the regulator. It is not a way to obtain a weight-loss drug early, and the number of people who go through it is small.

Everything else sold as retatrutide is an unapproved product from an unregulated supplier. Which raises the question of what is actually in it — and unusually, somebody has measured.

What is actually in the vials

In 2026 a team at the University of Queensland published an analysis of three products sold as retatrutide in Australia, each labelled 10 mg, submitted anonymously to a community drug-testing service and analysed by an accredited laboratory.

The first finding is not the one people expect. All three vials contained genuine retatrutide — the measured molecular weight matched authentic retatrutide at 4730.477 Da. And the contamination screen was reassuring: arsenic, cadmium, chromium, nickel and mercury were all below quantitation limits, and the lead that was detected came to 0.14% of the permitted daily exposure for an injectable. On the two things buyers worry about most, counterfeiting and poison, these samples were fine.

The problem was the dose.

Three vials of the same nominal strength, and the actual content ranged from half the label to nearly double it — a spread of almost four-fold between the weakest and the strongest.

Consider what that means alongside the phase 2 results above, where the difference between 4 mg and 8 mg was five and a half percentage points of body weight, and where the adverse events were explicitly dose-related. Someone measuring out what they believe is 4 mg from sample 1 is taking about 2 mg; from sample 2, about 7.6 mg. Same powder, same label, same intended dose, and nearly quadruple the drug.

This is the concrete reason a titration schedule for an unapproved molecule is not just legally awkward but arithmetically meaningless. A dose is a number multiplied by a concentration, and in this market the concentration is unknown to everyone including the seller. The same paper notes Australian media reports of severe adverse events attributed to purported retatrutide, including acute liver failure, and the BMJ published a fact check in July 2026 examining reports of a death.

Our page on what the FDA databases actually show covers the regulatory side of the same market.

Why this page has no dosing section

Other sites publish a retatrutide titration schedule. We are not going to, and it is worth saying why rather than leaving a gap.

There is no approved dose. Any schedule published today would be reconstructed from trial protocols — doses given under medical supervision, with monitoring, to people who consented to an experiment. Reprinting them as instructions changes what they are. And since the only way to act on those instructions is to buy an unregulated product from a seller the FDA is writing letters to, publishing them supplies the missing piece of that transaction.

When retatrutide is approved there will be a label, and a label is a dose. Until then the honest answer to "how much should I take" is that nobody can tell you, including the people who are selling it.

The molecules closest behind it

Two others in phase 3 are covered in depth: CT-388, Roche's signalling-biased dual agonist, and eloralintide, an amylin drug that reached 20% weight loss with no GLP-1 activity — and which is being studied in combination with tirzepatide rather than against it.

Everything on retatrutide

• What is retatrutide? — the ninety-second answer, availability first.
• Retatrutide weight loss — both trials dose by dose, and why 15.3% is the more impressive figure.
• Retatrutide side effects — what two trials reported, and why no incidence table exists.
• Retatrutide vs Zepbound — the head-to-head is running; here is its number.
• Retatrutide vs Wegovy — the widest gap, and the one thing Wegovy owns.
• Retatrutide vs Ozempic — the diabetes trial is the real comparison.